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Summary
Objective: We investigated how aging effects human chondrocyte yield, proliferation, post-expansion chondrogenic capacity, and response
to specific growth factors supplemented during expansion.
Methods: Fifty-two samples of human articular cartilage were harvested from cadavers 20 to 91 years old and grouped into age decades.
Cell yields were normalised to tissue wet weight. Cell proliferation rates were calculated during expansion in medium without (CTR) or with
TGF1, FGF-2 and PDGF-BB (TFP). Chondrogenic capacity of CTR- and TFP-expanded cells was assessed by cultivation as 3D pellets in
a defined serum-free medium, followed by histological, immunohistochemical, biochemical and real-time RT-PCR analyses.
Results: Cell yields were similar in donors up to 40 years of age and significantly lower (1.8-fold) in older donors. Cell proliferation rates in
CTR medium significantly decreased after 30 years of age and remained similar in older donors. In the presence of TFP, proliferation rates
were higher (up to 3.7-fold) in all age groups and decreased only slightly with age. The glycosaminoglycan (GAG) content of pellets obtained
from CTR-expanded cells was not correlated with age. Pellets from TFP-expanded cells reproducibly contained more GAG (up to 3.2-fold)
than those from CTR-expanded cells only if donors were younger than 40. Safranin O staining intensity and collagen type II expression and
accumulation were consistent with GAG contents.
Conclusion: Medium supplementation with the growth factor combination TFP during chondrocyte expansion supports higher proliferation
rates at any age and higher post-expansion chondrogenic capacity in donors up to 40 years. These findings may be relevant for
chondrocyte-based cartilage repair procedures.
© 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Articular cartilage is an avascular tissue that has a limited
capacity for self repair. Recently proposed cell-based car-
tilage repair procedures require that autologous articular
chondrocytes are isolated from a small biopsy, expanded
in vitro, and then either directly injected into the defect1 or
used to engineer implantable grafts2–4. Some aspects that
challenge the use and clinical outcome of cartilage repair
procedures, based on cells obtained from a small biopsy of
autologous cartilage are: (i) the limited number of chondro-
cytes available, (ii) the reproducible expansion of chondro-
cytes while preserving their chondrogenic potential, and
(iii) the re-differentiation and cartilage tissue formation
capacity of chondrocytes after expansion. These aspects
could have larger influences on the clinical procedure with
increasing donor age.
Aging has been shown to cause changes in the mech-
anical properties of articular cartilage5,6, in the molecular
composition, structure and organisation of the cartilage
matrix7–11, in the synthetic and metabolic activity of
chondrocytes9,12–14 and in their growth factor
responsiveness15–18. However, relatively little is known
about the effect of aging on chondrocyte yield, proliferation
and redifferentiation ability. Cell density of human cartilage
was reported to decrease with donor age19, which could
account for a reduced yield of chondrocytes from older
donors. However, no data are available on the number of
chondrocytes per unit weight which can be isolated from
tissue biopsies of donors of different ages. Age-related
differences in chondrocyte proliferation ability have
been investigated mostly in animal models. Evans and
Georgescu20 showed that the replication rate of lapine
chondrocytes is inversely related to the age of the donor
rabbit. Similarly, an age related decrease in lapine chondro-
cyte number at confluence, along with an increased cell
cycle time was observed by Adolphe et al.21. Guerne et al.
were the first to extensively study age-related changes in
human articular chondrocytes using monolayer cultures22.
The main observation was a profound decline in prolifer-
ation and growth factor responsiveness of chondrocytes as
a function of increasing donor age22. However, for this
study chondrocytes were cultured only for a short time (3–5
days), and therefore the obtained data are not directly
applicable to chondrocyte growth for cartilage repair
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procedures, since in this case extensive cell expansion
(i.e., for a period of 2–3 weeks) is required. Regarding the
chondrogenic ability of expanded chondrocytes, an age-
related reduction in growth factor-modulated cartilage
matrix production has been documented using non-human
primate and rat cells15,16. However, to our knowledge, no
study has addressed how aging influences the capacity of
expanded human articular chondrocytes to redifferentiate
and form cartilaginous tissues.
With the ultimate goal of defining conditions enabling
efficient and reproducible generation of autologous cell-
based chondrogenic grafts for articular cartilage repair, in
this study we investigated possible effects of donor age
on human chondrocyte (i) yield, (ii) proliferation rate and
(iii) post-expansion chondrogenic capacity. In addition, we
tested the hypothesis that expansion of human articular
chondrocytes in the presence of TGF1, FGF-2, PDGFbb
(TFP), previously shown to enhance cell proliferation and
post-expansion differentiation ability23, modulates age-
related chondrocyte changes.
Methods
CARTILAGE SAMPLES COLLECTION
Human articular cartilage was obtained post mortem
(within 24 h after death) from the knee joints of a total of 69
patients who had no known clinical history of joint dis-
orders. Since 17 specimens from donors over 40 years of
age were judged macroscopically not normal after visual
inspection (i.e., they were yellow in color or fibrillated at
the surface), only the remaining 52 were included in this
study (mean donor age: 49 years; range: 20–91; ratio
males:females: 5:1). Cartilage tissues were grouped in six
age groups as follows: 20–29 years (20s), 30–39 years
(30s), 40–49 years (40s), 50–59 years (50s), 60–69 years
(60s), 70–91 years (>70). One part of each cartilage biopsy
was used for histological scoring, the remainder (0.5 to
1.0 g) was minced and digested enzymatically to isolate
and use cells as described below.
CHONDROCYTE ISOLATION AND EXPANSION
Chondrocytes were isolated using 0.15% type II colla-
genase (10 ml solution/g tissue) for 22 h and resuspended
in Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal bovine serum, 4.5 mg/ml D-Glucose, 0.1 mM
nonessential amino acids, 1 mM sodium pyruvate, 100 mM
HEPES buffer, 100 U/ml penicillin, 100 µg/ml streptomycin,
and 0.29 mg/ml L-glutamine (complete medium). The iso-
lated chondrocytes were counted using trypan blue, plated
in tissue culture flasks at a density of 104 cells/cm2 and
cultured in complete medium, either without growth factors
(control medium, CTR) or with the addition of 1 ng/ml of
transforming growth factor-1 (TGF-1), 5 ng/ml of fibro-
blast growth factor-2 (FGF-2) and 10 ng/ml of platelet-
derived growth factor-BB (PDGF-BB) (growth factor
medium, TFP) in a humidified 37°C/5% CO2 incubator. The
growth factor combination was selected based on the
previously reported ability to increase human chondrocyte
proliferation and capacity to redifferentiate23. After approxi-
mately 10 days, when cells were about 80% confluent, first
passage cells (P1) were rinsed with phosphate buffered
saline (PBS), detached using 0.05% trypsin/0.53 mM EDTA
and replated at 5×103 cells/cm2. After one more week,
when cells were again about 80% confluent, second
passage cells (corresponding to a total of 4.6±0.9 and 8.1±
1.0 doublings respectively in CTR and TFP media) were
detached and induced to redifferentiate in pellet cultures as
described below.
3D-PELLET CULTURES
The chondrogenic capacity of expanded chondrocytes
was investigated in pellet cultures using a defined serum-
free medium, as previously described24,25. Cells were
suspended in DMEM supplemented with ITS+1 (Sigma
Chemical, St. Louis, MO; i.e., 10 µg/ml insulin, 5.5 mg/ml
transferrin, 5 ng/ml selenium, 0.5 mg/ml bovine serum
albumin, 4.7 mg/ml linoleic acid), 0.1 mM ascorbic acid
2-phosphate, 1.25 mg/ml human serum albumin, 10−7 M
dexamethasone and 10 ng/ml TGF-1 (chondrogenic
medium, CHM). Aliquots of 5×105 cells/0.5 ml were centri-
fuged at 250×g for 5 min in 1.5 ml polypropylene conical
tubes (Sarstedt, Nu¨mbrecht, Germany) to form spherical
pellets, which were placed onto a 3D orbital shaker
(Bioblock Scientific, Frenkendorf, Switzerland) at 30 rpm.
Pellets were cultured for 2 weeks, with medium changes
twice per week, and subsequently processed for histologi-
cal and immunohistochemical, biochemical or mRNA analy-
sis as described below. Each analysis was performed
independently in at least two entire pellets for each primary
culture and expansion condition.
ANALYTICAL METHODS
Proliferation rate
Cell proliferation rate was calculated as the ratio of T to
log2 (N/N0), where N0 and N are the numbers of cells
respectively at the beginning and the end of the expansion
phase, and T is the time required for the expansion24.
Histological and immuhistochemical analyses
Native tissues were stained with Safranin O and scored
according to Mankin et al.26 to assess state of degenera-
tion. Sections considered osteoarthritic were not used in
the study. Cultured cell pellets were fixed in 4% formalin,
embedded in paraffin, cross-sectioned (5 µm thick) and
stained with Safranin O for sulfated glycosaminoglycans
(GAG). Sections were also processed for immunohisto-
chemistry to visualize collagen type II (II-II6B3, Hybridoma
Bank, University of Iowa, USA), as previously described27.
Biochemical analyses
To measure total GAG amounts of native cartilage and
cell pellet cultures, each sample was digested with
protease K (0.5 ml of 1 mg/ml protease K in 50 mM Tris
with 1 mM EDTA, 1 mM iodoacetamide, and 10 µg/ml
pepstatin-A for 15 h at 56°C)28. GAG amounts were
measured spectrophotometrically using dimethylmethylene
blue29, with chondroitin sulfate as a standard, and normal-
ized to the DNA amounts, measured spectrofluorometri-
cally using the CyQUANT Kit (Molecular Probes, Eugene,
OR) and with calf thymus DNA as a standard. GAG
contents are reported as µg GAG/µg DNA.
Total RNA extraction and cDNA synthesis
For total RNA extraction provided by the native tissue,
each sample was crushed under liquid nitrogen, collected
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in cell lysis buffer from the RNeasy Kit (Qiagen, Basel,
Switzerland) and passed through a Qiashredder column
(Qiagen). The RNA was then isolated from this mix using
the RNeasy Kit (Qiagen), which included DNase treatment
(RNase-Free DNase Set, Qiagen). RNA was extracted
from cell pellet cultures using Trizol (Life Technologies,
Basel, Switzerland) and the standard single-step acid-
phenol guanidinium method30. Pellet cultures were firstly
sonicated for 1 min while in Trizol. The isolated RNA was
treated with DNAseI using the DNA-free Kit (Ambion,
Austin, TX) and quantified spectrophotometrically. cDNA
was generated from 3 µg of RNA by using 500 µg/ml
random hexamers (Promega, Madison, WI) and 1 µl of 50
units/ml Stratascript reverse transcriptase (Stratagene,
Cambridge, MA), in the presence of dNTPs.
Real-time reverse transcriptase-polymerase chain
reaction (RT-PCR) quantitative assays
PCR reactions were performed and monitored using the
ABI Prism 7700 Sequence Detection System (Perkin-
Elmer/Applied Biosystems, Rotkreuz, Switzerland). The
PCR master mix was based on AmpliTaq Gold DNA polym-
erase (Perkin Elmer/Applied Biosystems). In the same
reaction, cDNA samples (5 µl for a total volume of 25 µl per
reaction) were analyzed both for collagen type II (CII) and
the reference gene 18-S ribosomal RNA (18-S rRNA),
using a multiplex approach (Perkin Elmer/Applied Biosys-
tems User Bulletin no. 2). The probe for 18-S rRNA was
fluorescently labelled with VIC (Perkim Elmer/Applied Bio-
systems) and 6-carboxy-tetramethylrhodamine (TAMRA),
whereas the probe for CII was labeled with 6-carboxy-
fluorescein (FAM) and TAMRA. Cycle temperatures and
times were as previously described31. For each cDNA
sample, the threshold cycle (Ct) value of each target
sequence was subtracted to the Ct value of 18-S, to derive
Ct. The level of expression of CII was calculated as 2Ct.
Each sample was assessed at least in duplicate for each
gene of interest.
The following primers and probes were used at the
concentrations indicated in parenthesis: CII-forward primer:
5′-GGCAATAGCAGGTTCACGTACA (900 nM), CII-reverse
primer: 5′-CGATAACAGTCTTGCCCCACTT (900 nM), CII-
probe: 5′-CCGGTATGTTTCGTGCAGCCATCCT (200 nM);
18-S-forward primer: 5′-CGGCTACCACATCCAAGGAA
(26 nM), 18-S-reverce primer: 5′-GCTGGAATTACCGCG
GCT (26 nM), 18-S-probe: 5′-TGCTGGCACCAGACTT
GCCCTC (50 nM).
STATISTICAL ANALYSIS
Statistical evaluation was performed using SPSS soft-
ware version 7.5 software (SPSS, Sigma Stat). Values
are presented as mean±standard deviation (SD). Differ-
ences between age groups were assessed by two-tailed
Student’s t-test or the Mann–Whitney test, in accordance
with the Levene’s test for homogeneity of variances, after
assessment of normality by skewness and kurtosis. Differ-
ences between CTR and TFP were assessed by unpaired
t-tests. Correlations between any selected parameter and
age or between collagen type II mRNA expression and
GAG content were assessed using two-tailed Pearson’s
tests. P values less then 0.02 were considered to indicate
statistically significant differences or correlations.
Results
NATIVE CARTILAGE SAMPLES
Mankin scores of cartilage specimens displayed an
expected progressive age-related increment (r=+0.828;
P<0.001), but remained below levels considered as overtly
pathologic (Table I).
CELL YIELD
No detectable age-related differences in cell viability, as
assessed by trypan blue dye exclusion, were observed
after cartilage digestion (data not shown). Cell yields sig-
nificantly decreased with age (r=−0.775; P<0.001), with a
reduction of 61% from the youngest to the oldest age
group. Cell yields displayed a marked and significant
decrease from age group 30s (7.9 million cells/gram tissue)
to age group 40s (4.5 million cells/gram tissue) and
remained similar in older donors (Fig. 1A).
CELL PROLIFERATION RATE
The proliferation rate of chondrocytes expanded in the
absence (CTR) or in the presence of the growth
factor combination TGF1, FGF-2, and PDGF-BB (TFP)
decreased with increasing age of the cartilage donors
(CTR: r=−0.741; P<0.001 and TFP: r=−0.498; P<0.001)
(Fig. 1B). Proliferation rates of CTR-expanded cells were
observed to decrease (by 24.5%) from age group 20s (0.26
doublings/day) to 30s (0.19 doublings/day) and then gradu-
ally decreased in older donors. The drop in proliferation
rate between the youngest and oldest age group was
49.4%. The presence of TFP during chondrocyte expan-
sion significantly increased the proliferation rate in all age
groups, such that the proliferation rate was gradually
decreasing with age for a total of only 29.4% between the
youngest and oldest age group, with no statistically signifi-
cant difference between adjacent groups (Fig. 1B). The
proliferative response to TFP significantly increased from
2.5-fold in age group 20s to 3.7-fold in age group 40s, with
only minor variations in older age groups (Fig. 1D).
Considering a relevant number of expanded cells neces-
sary for grafting (i.e., 10 million cells) and a reasonable
period of time to reach such number (i.e., 2 weeks), based
on our results on the cell yields and proliferation rates the
use of TFP would reduce the required biopsy weight from
88 mg to 3 mg for the age group 20s and from 826 mg to
45 mg for the age group 70s. Conversely, considering the
same target number of expanded cells (i.e., 10 million cells)
and a reasonable biopsy weight of 100 mg, the use of TFP
would reduce the necessary expansion time from 13 to 6
days for the age group 20s and from 38 to 11 days for the
age group 70s.
Table I
Mankin score of cartilage tissues from different age groups
Age group Mankin score
20–29 0.0±0.0
30–39 0.7±0.6
40–49 1.5±0.7
50–59 2.8±1.2
60–69 4.0±0.6
70–91 4.1±1.7
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Fig. 1. Chondrocytes isolated from 52 individuals were expanded in medium without (CTR) or with TGF1, FGF-2 and PDGF-BB (TFP)
for two passages and then cultured as pellets in a defined medium promoting chondrogenic differentiation (see Methods). Age related
changes in: (A) chondrocyte yields; (B) proliferation rates of cells expanded in CTR or TFP medium; (C) sulfate glycosaminoglycan
content normalized to the amount of DNA (GAG/DNA) in the pellets generated by chondrocytes expanded in CTR or TFP; (D)
chondrocyte response to TFP during expansion in terms of proliferation and GAG content of the resulting pellets. In the left diagrams
values from each cartilage specimen are plotted; in the right diagrams, values are the mean±SD of samples grouped in decades of age.
*=P<0.02 from the previous age group, °=P<0.02 from CTR expanded cells.
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CELL CHONDROGENIC CAPACITY
The GAG content of pellets generated by cells expanded
without growth factors (CTR) was not correlated with donor
age (r=−0.366; P>0.02), and no statistically significant
difference between adjacent age groups was found (Fig.
1C). TFP-expanded chondrocytes generated pellets with
significantly higher GAG content than CTR-expanded cells
from donors in the age groups 20s (3.3-fold) and 30s
(2.8-fold) (Fig. 1C). The GAG content of pellets formed by
TFP-expanded cells markedly decreased with donor age
(r=−0.676; P<0.001), although, due to relatively large inter-
individual variability, no statistically significant difference
between adjacent age groups was found (Fig. 1C). In the
age group 40s, both CTR- and TFP-expanded chondro-
cytes generated pellets with the highest variability in GAG
content (Fig. 1C). Changes in pellet GAG contents in
response to TFP supplemented during cell expansion sig-
nificantly decreased from 3.3-fold in the age group 20s to
1.5-fold in the age group 40s, with only minor variations
in older age groups (Fig. 1D). Such average reduction
corresponds to the fact that only chondrocytes from some
donors older than 40 years responded to TFP during
expansion by increasing GAG accumulation in the resulting
pellets.
Representative pellets stained by Safranin O are shown
in Fig. 2. Qualitative observations of staining intensity and
cellular density confirmed that (i) CTR-expanded cells from
younger and older donors generated poor quality cartilagi-
nous tissues (Fig. 2; I, III, V, VII), (ii) changes induced by
TFP during expansion were remarkable in cells from young
donors (Fig. 2; I vs II) and (iii) TFP-expanded chondrocytes
from donors in the age group 40s had highly variable
chondrogenic capacities (Fig. 2; IV vs VI).
Biochemically measured GAG contents correlated with
the mRNA expression of collagen type II (r=+0.685;
P<0.001) (Fig. 3A). Moreover, pellets that were more
intensely stained for Safranin O generally contained higher
amounts of collagen type II protein, as assessed by immu-
nohistochemical staining (Fig. 3B). No correlation between
GAG contents and cell proliferation rate was found in any
age group.
Discussion
In the present study, we investigated the effect of age on
three parameters relevant for cell-based cartilage repair
procedures, namely chondrocyte yield, proliferation rate
and post-expansion chondrogenic capacity. The analyzed
parameters displayed different trends as a function of
increasing donor age: (i) cell yields were markedly reduced
after the age group 30s, (ii) cell proliferation rates in CTR
medium declined after age group 20s and only slightly
decreased with age in older donors, and (iii) post-
expansion chondrogenic capacities of cells expanded in
CTR medium were not correlated with age. The use of the
growth factor combination TGF1, FGF-2, and PDGF-BB
(TFP) during cell expansion supported higher proliferation
rates at any age range but preferentially in donors older
than 30s, thus reducing age-related changes in the prolifer-
ation rate. Furthermore, TFP expansion induced an
increase in the GAG content of pellets formed by chondro-
cytes from individuals of the age groups 20s and 30s,
thus introducing a marked age-related decrease in the
post-expansion cell chondrogenic capacity.
Isolation of chondrocytes from a cartilage biopsy is the
first ex-vivo step to generate a cell-based cartilage graft.
Our results indicate a decrease in chondrocyte yield with
age, which is qualitatively and quantitatively consistent
with the documented reduced cellularity of aging
cartilage19,32–34. The extent of reduction measured in
chondrocyte yield from the youngest to the oldest age
group (61%) is similar to the total decrease in cellular
density (about 50%) reported by Quintero et al.33. The age
range corresponding to the greatest decline in chondrocyte
yield found in our study (between the age groups 30s and
40s) is also consistent with that corresponding to the major
decrease in chondrocyte density (between birth and the
third decennium) reported by Leutert et al.19. However,
other mechanisms besides an age-related decline in cell
density (e.g., survival capacity of chondrocytes to enzy-
matic digestion or efficacy of their extraction) could be
involved in the age-related reduction of cell yields.
Chondrocyte expansion is the second ex vivo step for
cell-based cartilage repair approaches, necessary to obtain
sufficient cell numbers. In accordance with the results
obtained studying articular chondrocytes from experimental
animals20,21,35, we observed an age-related reduction in
the proliferation rates of human articular chondrocytes. In
the absence of growth factors, the greatest decrease
between two adjacent groups was seen between the age
groups 20s and 30s. Guerne et al. in a previous study22
reported that the greatest reduction in DNA synthesis
during expansion of human chondrocytes for 3–5 days,
was from donors after the age group 40s. This difference
may be explained by the fact that in the present study cell
proliferation rates were assessed in a longer time frame
(about 20–30 days).
Guerne et al. in the same study22 observed a marked
age-related decline in the proliferative response of
chondrocytes to TGF1. Our data demonstrated that the
growth factor combination TFP has a stronger proliferative
effect in cells from donors older than 40, and thus substan-
tially contributes to reducing age-related changes in
chondrocyte proliferation rates.
Since the cause of age-related decrease in chondrocyte
proliferation ability has been associated with cell sen-
escence, as assessed by increased expression of the
senescence-associated enzyme beta-galactosidase and
erosion of telomere length36,37, further studies should aim
at investigating the effects of TFP on these markers of cell
senescence. Since the effects of TFP could be modulated
by the presence of other serum components, it will also be
important to study chondrocyte response to TFP in media
containing different serum concentrations.
We then evaluated the effect of donor age on the
post-expansion chondrogenic capacity of human chondro-
cytes using a 3D pellet culture model. Great variability of
GAG contents was observed using cells from donors not
only of different ages, but also within the same age group.
The large variability observed in the chondrogenic capacity
of chondrocytes from different individuals could be due to
factors of a variety of nature, such as previous drug
treatments, life style, sport activities and/or to the presence
of different subpopulation of chondrocytes contained in
different cartilage biopsies. The large variability in the
quality of the pellets generated by chondrocytes from
different donors, even within the same age group, prompts
for further studies to identify chondrocyte markers
associated with enhanced chondrogenic potential. The
presence of TFP during chondrocyte expansion was
previously shown to increase both proliferation rates and
post-expansion chondrogenic capacity of human adult
articular chondrocytes23. The present study more precisely
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indicates that TFP induces both effects in chondrocytes
from young individuals (less than 40 years), but increases
only proliferation rates in cells from older donors. This
suggests that the proliferative and chondrogenic capacities
of human articular chondrocytes are regulated by TFP
through different mechanisms. Such mechanisms could
include events related to integrin mediated binding of
collagen type II, as proposed by Lee et al.38.
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Fig. 2. Safranin O staining of pellets obtained from chondrocytes expanded without (I, III, V, VII) or with TFP (II, IV, VI, VIII) and derived from
donors aged 32 (I and II), 43 (III and IV), 45 (V and VI) and 67 years (VII and VIII). Corresponding GAG contents (mean of two
pellets/condition±SD) were: (I) 3.1±0.2, (II) 11.2±0.7, (III) 2.1±0.2, (IV) 4.1±0.4, (V) 4.8±0.5, (VI) 8.9±0.8, (VII) 2.3±0.2, (VIII) 1.8±0.1.
Bar=200 µm.
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From a clinical prospective, our findings suggest that the
growth factor combination TFP could be used during
human articular chondrocyte expansion to increase (i) the
amplification efficiency of cells from donors of any age, and
(ii) the chondrogenic ability of cells from donors up to 40
years (corresponding to the patient population typically
treated using cultured chondrocytes). Considering a fixed
target number of cells required for grafting (either directly or
after loading into a scaffold), medium supplementation with
TFP during expansion would markedly reduce either the
time necessary to reach that number starting from the
same biopsy or the weight of the biopsy necessary to reach
that cell number in the same time. As compared to corre-
sponding CTR-expanded cells, the chondrogenic capacity
of the TFP-expanded cells would then be reproducibly
superior for patients up to 40 years of age or only slightly
improved in a few cases for older patients, but never
reduced. The relevance of these studies would be further
strengthened by in vivo studies (i) investigating the tissue
regeneration capacity of cells expanded with or without
TFP and (ii) testing if the quality of the tissue generated in
our in vitro model correlates with the in vivo capacity of
chondrocytes to repair and/or regenerate cartilage tissue.
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